Refer A Patient

Request An Appointment

Other

ILARIS

ILARIS (canakinumab) works to suppress the production of an inflammatory protein.
Infusion or injection therapy referral
What it treats Cryopyrin-associated Periodic Syndromes (CAPS),
including Familial Cold Autoinflammatory Syndrome (FCAS);
Muckle-Wells Syndrome (MWS);
Neonatal Onset Multisystem Inflammatory Disease (NOMID);
Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS);
Hyper-Immunoglobulin D Syndrome (HIDS);
Mevalonate Kinase Deficiency (MKD);
Familial Mediterranean Fever (FMF);
Adult Onset Still’s Disease (AOSD);
Systemic Juvenile Idiopathic Arthritis (SJIA)
Prescribed by Various medical specialists
How it’s administered Subcutaneous injection
Frequency Monthly or bi-monthly
Length of treatment 10 to 15 minutes

About This Therapy

ILARIS (canakinumab) works to suppress the production of an inflammatory protein. Increased levels of the inflammatory protein IL-1β cause inflammation resulting in symptoms such as fever, joint pain, and rashes. ILARIS stops this inflammatory response.

For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.

ILARIS REFERRAL FORM

ILARIS REFERRAL FORM

Speak with your healthcare provider to learn if this therapy is right for you, then complete the referral form below.
REFERRAL FORM →

Ready to refer a patient for ILARIS

Our team handles benefits verification, prior authorization, and scheduling so you can focus on care.